OverviewSuggest Edit
Biogen is a biopharmaceutical company that discovers, develops, and delivers innovative therapies for people living with serious neurological and neurodegenerative diseases. It is primarily focused on developing medicines to treat multiple sclerosis, spinal muscular atrophy, Alzheimer’s disease, Parkinson’s disease, and amyotrophic lateral sclerosis. The company also manufactures and commercializes biosimilars of advanced biologics.
| Type | Public | |
| Founded | 1978 | |
| HQ | Cambridge, MA, US | Map |
| Website | biogen.com | |
| Employee Ratings | More | |
| Overall Culture | B | More |
Recent NewsAll News
- Sage Therapeutics to receive $1.525 billion in cash in deal with Biogen to jointly develop depression, tremor therapies
- Biogen and Sage Therapeutics Announce Global Collaboration to Develop and Commercialize Potential Breakthrough Therapies in Depression and Movement Disorders
- BIIB INVESTOR FILING DEADLINE: Bernstein Liebhard LLP Reminds Investors of the Deadline to File a Lead Plaintiff Motion in a Securities Class Action Lawsuit Against Biogen Inc.
- ROSEN, A TOP RANKED LAW FIRM, Reminds Biogen Inc. Investors of Important January 12 Deadline in First Filed Securities Class Action Commenced by the Firm; Encourages Investors with Losses in Excess of $1 Million to Contact the Firm – BIIB
Key People/Management at Biogen
Michel Vounatsos
Chief Executive Officer and Director
Susan Alexander
Executive Vice President, Chief Legal Officer and Secretary
Stelios Papadopoulos
Chairman of the Board
Michael McDonnell
Executive Vice President, CFO
Alphonse Galdes
Executive Vice President, Pharmaceutical Operations and Technology
Ginger Gregory
Executive Vice President, Chief Human Resource Officer
Biogen Office Locations
Biogen has offices in Cambridge, Morrisville, Waltham, Washington and in 35 other locations
Cambridge, MA, US (HQ)
225 Binney St
Morrisville, NC, US
5000 Davis Dr
Waltham, MA, US
203 Crescent St #303
Washington, DC, US
601 Pennsylvania Ave NW #720
Weston, MA, US
133 Boston Post Rd
Vicente López, AR
7th Floor, Av. del Libertador 350
Biogen Financials and Metrics
Biogen Revenue
Biogen's revenue was reported to be $14.38 b in FY, 2019 which is a 6.9% increase from the previous period.
| USD | |
|---|---|
Revenue (Q3, 2020) | 2.7b |
Market capitalization (3-Dec-2020) | 37.6b |
Closing stock price (3-Dec-2020) | 244.1 |
Cash (30-Sept-2020) | 2.2b |
EV | 35.7b |
Biogen's current market capitalization is $37.6 b.
Annual
Quarterly
| USD | Q1, 2017 | Q2, 2017 | Q3, 2017 | Q1, 2018 | Q2, 2018 | Q3, 2018 | Q1, 2019 | Q2, 2019 | Q3, 2019 | Q1, 2020 | Q2, 2020 | Q3, 2020 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
Revenue | 2.8b | 3.1b | 3.1b | 3.1b | 3.4b | 3.4b | 3.5b | 3.6b | 3.6b | 3.5b | 3.7b | 2.7b |
Cost of goods sold | 384.6m | 366.2m | 370.0m | 446.0m | 421.0m | 460.8m | 602.0m | 476.3m | 430.0m | 454.3m | 411.1m | |
Gross profit | 2.4b | 2.7b | 2.7b | 2.7b | 2.9b | 3.0b | 2.9b | 3.1b | 3.2b | 3.1b | 3.3b | |
Gross profit Margin, % | 86% | 88% | 88% | 86% | 87% | 87% | 83% | 87% | 88% | 87% | 89% |
Annual
Quarterly
| USD | Q1, 2017 | Q2, 2017 | Q3, 2017 | Q1, 2018 | Q2, 2018 | Q3, 2018 | Q1, 2019 | Q2, 2019 | Q3, 2019 | Q1, 2020 | Q2, 2020 | Q3, 2020 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
Cash | 924.0m | 1.2b | 1.5b | 4.1b | 1.3b | 2.4b | 2.2b | 1.7b | 2.3b | 2.6b | 2.4b | 2.2b |
Accounts Receivable | 1.5b | 1.6b | 1.6b | 1.9b | 2.0b | 2.0b | 2.1b | 2.0b | 1.9b | 2.1b | 2.1b | 2.0b |
Inventories | 921.6m | 936.5m | 1.0b | 890.8m | 931.7m | 916.6m | 770.2m | 776.7m | 751.8m | 858.8m | 952.7m | 1.0b |
Current Assets | 6.9b | 7.1b | 7.6b | 10.2b | 7.4b | 8.7b | 8.9b | 7.9b | 8.4b | 8.0b | 8.5b | 7.8b |
Annual
Quarterly
| USD | Q1, 2017 | Q2, 2017 | Q3, 2017 | Q1, 2018 | Q2, 2018 | Q3, 2018 | Q1, 2019 | Q2, 2019 | Q3, 2019 | Q1, 2020 | Q2, 2020 | Q3, 2020 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
Net Income | 747.5m | 1.6b | 2.8b | 1.2b | 2.1b | 3.5b | 1.4b | 2.9b | 4.4b | 1.4b | 3.0b | 3.7b |
Depreciation and Amortization | 512.0m | 814.6m | 992.0m | 168.9m | 340.4m | 686.9m | 121.1m | 238.1m | 567.6m | 119.9m | 232.8m | 366.8m |
Inventories | (46.2m) | (85.3m) | (170.3m) | (2.6m) | (40.1m) | (31.9m) | (129.0m) | (108.7m) | (47.3m) | (62.2m) | (188.2m) | (270.6m) |
Cash From Operating Activities | 235.2m | 1.4b | 3.0b | 1.5b | 2.6b | 4.3b | 1.5b | 3.4b | 5.1b | 1.5b | 3.4b | 4.6b |
| USD | Q1, 2017 |
|---|---|
Debt/Equity | 0.6 x |
Debt/Assets | 0.3 x |
Financial Leverage | 1.8 x |
Biogen Acquisitions / Subsidiaries
| Company Name | Date | Deal Size |
|---|---|---|
| Nightstar Therapeutics | March 04, 2019 | $800 m |
| AliveGen | July 25, 2018 | $27.50 m |
| Karyopharm Therapeutics | January 25, 2018 | $10 m |
| Remedy Pharmaceuticals | May 18, 2017 | $120 m |
| Convergence Pharmaceuticals | February 14, 2014 | $675 m |
| Stromedix | February 14, 2014 | $75 m |
| Tysabri | February 28, 2013 | |
| Syntonix Pharmaceuticals | January 04, 2007 | $120 m |
| Fumapharm | May 31, 2006 | |
| Conforma Therapeutics | May 03, 2006 | $150 m |
Biogen Revenue Breakdown
Biogen revenue breakdown by business segment: 15.9% from Anti-CD20 Therapeutic Programs, 79.1% from Product Revenues and 4.9% from Other
Biogen Cybersecurity Score
Biogen Online and Social Media Presence
35.36k Twitter followers
Biogen has 35.36k Twitter Followers. The number of followers has increased 3.2% month over month and increased 6.4% quarter over quarter
Biogen's Trends
Twitter Engagement Stats for @biogen
4.8k
Tweets
255
Following
35.4k
Followers
53
Tweets last 30 days
13.8
Avg. likes per Tweet
100%
Tweets with engagement
Biogen Company Culture
Overall Culture
B
72/100
CEO Rating
C-
65/100
Compensation
A+
84/100
Diversity
A
81/100
Biogen News and Updates
November 27, 2020
Sage Therapeutics to receive $1.525 billion in cash in deal with Biogen to jointly develop depression, tremor therapies
Biogen Inc. and Sage Therapeutics Inc. said Monday they have agreed to jointly develop therapies to treat depression and movement disorders in a deal in which Biogen will give Sage $1.525 billion in cash. The money will be split between an upfront payment of $875 million and a $650 million equity …
November 27, 2020
Biogen and Sage Therapeutics Announce Global Collaboration to Develop and Commercialize Potential Breakthrough Therapies in Depression and Movement Disorders
CAMBRIDGE, Mass., Nov. 27, 2020 (GLOBE NEWSWIRE) -- Biogen Inc. (Nasdaq: BIIB) and Sage Therapeutics, Inc. (Nasdaq: SAGE) announced that they have executed a global collaboration and license agreement to jointly develop and commercialize zuranolone (SAGE-217) for major depressive disorder (MDD), p…
November 24, 2020
BIIB INVESTOR FILING DEADLINE: Bernstein Liebhard LLP Reminds Investors of the Deadline to File a Lead Plaintiff Motion in a Securities Class Action Lawsuit Against Biogen Inc.
NEW YORK, Nov. 24, 2020 (GLOBE NEWSWIRE) -- Bernstein Liebhard, a nationally acclaimed investor rights law firm, reminds investors of the deadline to file a lead plaintiff motion in a securities class action lawsuit that has been filed on behalf of investors who purchased or acquired the securitie…
November 22, 2020
ROSEN, A TOP RANKED LAW FIRM, Reminds Biogen Inc. Investors of Important January 12 Deadline in First Filed Securities Class Action Commenced by the Firm; Encourages Investors with Losses in Excess of $1 Million to Contact the Firm – BIIB
NEW YORK, Nov. 22, 2020 (GLOBE NEWSWIRE) -- Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of Biogen Inc. (NASDAQ: BIIB), between October 22, 2019 and November 6, 2020, inclusive (the “Class Period”) of the important January 12, 2021 lead plaintiff deadline…
November 18, 2020
Samsung Bioepis and Biogen Announce FDA Filing Acceptance of SB11, A Proposed Biosimilar Referencing Lucentis® (ranibizumab)
INCHEON, South Korea and CAMBRIDGE, Mass., Nov. 18, 2020 (GLOBE NEWSWIRE) -- Samsung Bioepis Co., Ltd. and Biogen Inc. (Nasdaq: BIIB) today announced that the U.S. Food and Drug Administration (FDA) has accepted for review the Biologics License Application for SB11, a proposed biosimilar referenci…
November 13, 2020
TOP RANKED ROSEN LAW FIRM Files First Securities Class Action Lawsuit Against Biogen Inc.; Encourages Investors with Losses in Excess of $500K to Contact the Firm - BIIB
NEW YORK, Nov. 13, 2020 /PRNewswire/ -- Rosen Law Firm, a global investor rights law firm, announces it has filed a class action lawsuit on behalf of purchasers of the securities of Biogen Inc. (NASDAQ: BIIB), between October 22, 2019 and November 6, 2020, inclusive (the "Class Period")....
Biogen Blogs
November 16, 2020
Biogen Ranked #1 Biotechnology Company by Dow Jones Sustainability World Index for an Industry Record 5th Time; Recognition Reflects Longstanding ESG Leadership
Biogen earns top scores on areas including access to medicine, talent attraction, innovation management and climate performance and reporting In 2013 Biogen became the 1 st U.S. biotech company to appear on the DJSI World Index 2020 marks the 8 th consecutive year that Biogen was listed among top
November 03, 2020
Biogen to Present Positive Phase 2 Systemic Lupus Erythematosus Data at American College of Rheumatology 2020 Meeting
Biogen to Present Positive Phase 2 Systemic Lupus Erythematosus Data at American College of Rheumatology 2020 Meeting
Content Import
Tue, 11/03/2020 - 07:30
Biogen to Present Positive Phase 2 Systemic Lupus Erythematosus Data at American College of Rheumatology 2020 Meeting
…
November 02, 2020
Biogen to Webcast Prerecorded Presentation on Aducanumab Embark Study Design and Live Q&A from CTAD on November 4, 2020
Biogen to Webcast Prerecorded Presentation on Aducanumab Embark Study Design and Live Q&A from CTAD on November 4, 2020
jo-en.bautista…
Mon, 11/02/2020 - 13:59
Biogen to Webcast Prerecorded Presentation on Aducanumab Embark Study Design and Live Q&A from CTAD on November 4, 2020
…
October 07, 2020
Biogen to Report Third Quarter 2020 Financial Results October 21, 2020
Cambridge, Mass. — Biogen Inc. (Nasdaq: BIIB) today announced it will report third quarter 2020 financial results Wednesday, October 21, 2020, before the financial markets open. Following the release of the financials, the Company will host a live webcast with Biogen management at 8:00 a.m. ET.
September 29, 2020
Statement about the FDA advisory committee on aducanumab
Statement about the FDA advisory committee on aducanumab
Ray.Beron@west.com
Tue, 09/29/2020 - 11:44
Statement about the FDA advisory committee on aducanumab
September 29, 2020 at 4:06 PM EDT
This release is a backfill from a News Wire
In…
September 29, 2020
Reactive Statement to ICER’s announced plans to conduct an assessment on the value of aducanumab
Reactive Statement to ICER’s announced plans to conduct an assessment on the value of aducanumab
Ray.Beron@west.com
Tue, 09/29/2020 - 11:43
Reactive Statement to ICER’s announced plans to conduct an assessment on the value of aducanumab
September 29, 2020 at 4:06 PM EDT
…
Biogen Frequently Asked Questions
When was Biogen founded?
Biogen was founded in 1978.
Who are Biogen key executives?
Biogen's key executives are Michel Vounatsos, Susan Alexander and Stelios Papadopoulos.
How many employees does Biogen have?
Biogen has 7,400 employees.
What is Biogen revenue?
Latest Biogen annual revenue is $14.4 b.
What is Biogen revenue per employee?
Latest Biogen revenue per employee is $1.9 m.
Who are Biogen competitors?
Competitors of Biogen include Covance, Sanofi Genzyme and EMD Serono.
Where is Biogen headquarters?
Biogen headquarters is located at 225 Binney St, Cambridge.
Where are Biogen offices?
Biogen has offices in Cambridge, Morrisville, Waltham, Washington and in 35 other locations.
How many offices does Biogen have?
Biogen has 39 offices.
Learn about Craft real-time company insights
Receive alerts for 300+ data fields across thousands of companies